ICD-10-CM Common Codes for Gynecology and Obstetrics ICD-10 Code Diagnoses Menstrual Abnormalities N91.2 Amenorrhea N91.5 Oligomenorrhea N92.0 Menorrhagia N92.1 Metrorrhagia N92.6 Irregular Menses N93.8 Dysfunctional Uterine Bleeding N94.3 Premenstrual Syndrome N94.6 Dysmenorrhea Disorders Of Genital Area L29.3 Vaginal Itch N73.9 N75.0 Bartholin’s Cyst N76.0
What is the code for hypokalemia?
K08.121 is a valid billable ICD-10 diagnosis code for Complete loss of teeth due to periodontal diseases, class I . It is found in the 2021 version of the ICD-10 Clinical Modification (CM) and can be used in all HIPAA-covered transactions from Oct 01, 2020 - Sep 30, 2021 .
Abnormally high concentration of calcium in the peripheral blood.
E58 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM E58 became effective on October 1, 2021. This is the American ICD-10-CM version of E58 - other international versions of ICD-10 E58 may differ.
ICD-10-CM code E83. 52 should be used to report management of hypercalcemia of malignancy.
Hypercalcemia can interfere with how your brain works, resulting in confusion, lethargy and fatigue. It can also cause depression. Heart. Rarely, severe hypercalcemia can interfere with your heart function, causing palpitations and fainting, indications of cardiac arrhythmia, and other heart problems.
Unspecified disorder of calcium metabolism E83. 50 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM E83. 50 became effective on October 1, 2021.
ICD-10-CM Code for Secondary hyperparathyroidism of renal origin N25. 81.
288.60 - Leukocytosis, unspecified | ICD-10-CM.
ICD-10 code D75. 839 for Thrombocytosis, unspecified is a medical classification as listed by WHO under the range - Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism .
ICD-10-CM Code for Hyperuricemia without signs of inflammatory arthritis and tophaceous disease E79. 0.
High Calcium Levels Hypercalcemia is defined as total blood calcium over 10.5 mg/dL [6, 7, 8]: 10.51 – 12 mg/dL is considered mild hypercalcemia and usually doesn't cause symptoms. 12 – 13 mg/dL is considered moderate hypercalcemia. 13 mg/dL and above is considered severe hypercalcemia.
Pamidronate is the most commonly used medication for the treatment of hypercalcemia. It is given by IV infusion over 4 to 24 hours. The initial dose varies: 30 mg if the calcium level is lower than 12 mg/dL, 60 mg if the calcium level is 12 to 13.5 mg/dL, and 90 mg if the calcium level is above that level.
Intravenous bisphosphonates are the treatment of first choice for the initial management of hypercalcaemia, followed by continued oral, or repeated intravenous bisphosphonates to prevent relapse.
When the tumor is no longer amenable to surgical intervention, treatment becomes focused on the control of hypercalcemia with medical therapy, which can include bisphosphonates, calcimimetic agents, or denosumab. (See "Parathyroid carcinoma", section on 'Treatment' .)
Hemodialysis should be considered, in addition to the above treatments, in patients who have serum calcium concentrations in the range of 18 to 20 mg/dL (4.5 to 5 mmol/L) and neurologic symptoms but a stable circulation or in those with severe hypercalcemia complicated by renal failure. (See 'Dialysis' below.)
Salmon calcitonin (4 international units/kg) is usually administered intramuscularly or subcutaneously every 12 hours; doses can be increased up to 6 to 8 international units/kg every six hours. Nasal application of calcitonin is not efficacious for treatment of hypercalcemia [ 12 ].
If a hypocalcemic response is noted, then the patient is calcitonin sensitive and the calcitonin can be repeated every 6 to 12 hours (4 to 8 international units/kg). Patients may develop tachyphylaxis to calcitonin after 24 to 48 hours, so therapy is usually limited to this time period and then discontinued.
Hypercalcemia may be associated with a spectrum of clinical manifestations, ranging from few or no symptoms in patients with mild chronic hypercalcemia to severe obtundation and coma (see "Clinical manifestations of hypercalcemia" ).
Calcitonin is safe and relatively nontoxic (other than mild nausea and the rare hypersensitivity reaction). Although a relatively weak agent, it works rapidly, lowering the serum calcium concentration by a maximum of 1 to 2 mg/dL (0.3 to 0.5 mmol/L) beginning within four to six hours ( table 1) [ 1,4,13,14 ].
In patients with hypercalcemia of malignancy, progressive hypercalcemia will inevitably accompany tumor progression, and therefore , the underlying disease causing the hypercalcemia should be treated, if at all possible.